Effects of COVID-19 on patients with autoimmune diseases
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
['FUNDING_R01'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-11018582
This study is looking at how COVID-19 affects people with autoimmune diseases like rheumatoid arthritis and lupus, to better understand their immune responses and how their treatments might change their reactions to the virus and vaccines, ultimately aiming to improve their health outcomes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11018582 on ClinicalTrials.gov |
What this research studies
This research investigates how COVID-19 affects individuals with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis and systemic lupus erythematosus. It focuses on understanding the immune responses of these patients, particularly how their treatments may influence their reactions to COVID-19 and vaccination. The study aims to identify the short-term and long-term health outcomes for these patients, including the risk of severe symptoms and prolonged effects after infection. By analyzing immune responses and clinical outcomes, the research seeks to provide insights that could improve care for this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic autoimmune rheumatic diseases, such as rheumatoid arthritis or systemic lupus erythematosus.
Not a fit: Patients without autoimmune diseases or those who have not contracted COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management strategies and treatments for patients with autoimmune diseases who contract COVID-19.
How similar studies have performed: Previous research has shown that patients with autoimmune conditions may experience unique challenges during COVID-19, indicating that this area of investigation is both relevant and necessary.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SPARKS, JEFFREY ANDREW — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: SPARKS, JEFFREY ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: acute phase of SARS-CoV-2 infection, acute SARS-CoV-2 infection, adverse sequelae of coronavirus disease, adverse sequelae of coronavirus disease 2019